Rossari Biotech shares surge 9% as Q3 FY26 revenue jumps 13% YoY, PAT up 3%Rossari Biotech shares surge 9% as Q3 FY26 revenue jumps 13% YoY, PAT up 3%

Introduction

Leading specialty chemicals manufacturer reported Q3 FY26 revenue of ₹581.7 crore, EBITDA of ₹68.9 crore, and net profit of ₹32.8 crore, showing steady year-on-year growth.

Also Read: CG Power rises 9% after securing massive ₹900 Cr transformer order for US data center project

Share price movement of Rossari Biotech

On January 20, 2026, Rossari Biotech Ltd opened at ₹521.30, down 0.14% from its previous close of ₹522.05. The stock reached a high of ₹566.05 (8.42%) and a low of ₹519.40 (-0.13%). By 10:54 AM, it traded at ₹534.85, a 2.45% increase, with a market cap of ₹2,962.07 crore.

Rossari Biotech Q3 Profit Rises

Rossari Biotech Limited reported Q3 FY26 consolidated revenue of ₹581.7 crore, rising 13% year-on-year from ₹512.7 crore, driven by improved demand across its specialty chemicals portfolio.

EBITDA for the quarter increased 6% year-on-year to ₹68.9 crore from ₹64.8 crore, while EBITDA margin declined to 11.8% compared with 12.6% in Q3 FY25.

Net profit after tax rose 3% year-on-year to ₹32.8 crore from ₹31.7 crore. Diluted earnings per share for Q3 FY26 stood at ₹5.9.

Stock performance of Rossari Biotech for Period of 1 week, 6 months, and 1 year

Rossari Biotech Ltd delivered a -4.24% return over the past week and declined 27.2% in the past 6 months. The stock fell 36.4% over the past 1 year.

Also Read: BHEL Q3 FY26: Profit jumps 190% YoY to ₹390 crore as revenue rises 16%

Shareholding pattern of Rossari Biotech

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	68.20%	68.20%	68.20%
FII	2.30%	2.70%	3.50%
DII	18.30%	18.20%	17.80%
Public	11.30%	11.00%	10.50%

About Rossari Biotech

Rossari Biotech Limited (NSE: ROSSARI) is a Mumbai-based specialty chemicals manufacturer offering solutions in HPPC, textile, and animal health, with manufacturing units in Silvassa and Dahej.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs